Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEAN Trial: Osimertinib and Cyclosporine in EGFR-Mutant NSCLC
NCT07874490Phase 2Recruiting
- Sponsor
- NYU Langone Health
- Start
- Oct 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
A Phase 2 trial of cyclosporine in non-small cell lung cancer (NSCLC), sponsored by NYU Langone Health. Started Oct 2026; status: recruiting.
02
Drugs
cyclosporine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07874490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07874490.